HC Wainwright Lifts Earnings Estimates for Compass Pathways

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Research analysts at HC Wainwright raised their Q2 2026 earnings estimates for shares of Compass Pathways in a research report issued on Friday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.36) per share for the quarter, up from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Compass Pathways’ Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($1.53) EPS, Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.85) EPS.

Several other research firms have also recently commented on CMPS. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Morgan Stanley boosted their price target on shares of Compass Pathways from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Thursday. Maxim Group boosted their price target on shares of Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a report on Friday. B. Riley Financial began coverage on shares of Compass Pathways in a report on Friday, April 24th. They set a “buy” rating and a $17.00 price target on the stock. Finally, Royal Bank Of Canada boosted their price target on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.58.

Compass Pathways Trading Up 1.8%

Compass Pathways stock opened at $10.56 on Tuesday. The company’s fifty day simple moving average is $7.30 and its 200-day simple moving average is $6.77. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. Compass Pathways has a 12 month low of $2.25 and a 12 month high of $11.65. The stock has a market cap of $1.43 billion, a P/E ratio of -3.35 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15.

Institutional Investors Weigh In On Compass Pathways

A number of large investors have recently bought and sold shares of the business. RTW Investments LP boosted its holdings in Compass Pathways by 0.6% in the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after purchasing an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC boosted its holdings in Compass Pathways by 47.7% in the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares in the last quarter. Millennium Management LLC boosted its holdings in Compass Pathways by 39.9% in the third quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after purchasing an additional 774,090 shares in the last quarter. Toronto Dominion Bank boosted its holdings in Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after purchasing an additional 1,529,013 shares in the last quarter. Finally, ARK Investment Management LLC boosted its holdings in Compass Pathways by 1.6% in the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after purchasing an additional 34,894 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Compass Pathways News Summary

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $70 price target on Compass Pathways while lifting multiple earnings estimates for 2026 and 2027, signaling continued optimism about the company’s longer-term outlook.
• Positive Sentiment: The firm improved its Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026 and FY2027 EPS forecasts, which can reinforce the bullish case for CMPS if investors view the revisions as evidence of improving fundamentals.
• Positive Sentiment: Trading activity also picked up, with unusual call option buying on Compass Pathways—often a sign that traders are positioning for a sharp move higher ahead of a potential catalyst.
• Positive Sentiment: Recent media coverage highlighted that retail traders believe a major FDA catalyst may be developing, adding to speculation around the stock and helping explain why shares have been strengthening. CMPS stock is breaking out again — retail traders think a major FDA catalyst is brewing
• Neutral Sentiment: Another article described CMPS as a momentum-driven psychedelics stock that continues to attract attention, but it did not add a new company-specific development beyond the ongoing speculation. This psychedelics stock just keeps getting hotter; why shares bypassed a profit-taking zone
• Negative Sentiment: Lifesci Capital reportedly cut earnings estimates for Compass Pathways, which is a reminder that not all analysts are turning more bullish on near-term profitability.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.